The problem calcium creates without K2
Calcium supplementation became standard women's health advice in the 1990s. More calcium, stronger bones. The logic made sense. But the research that followed — particularly the Women's Health Initiative calcium trials — showed something uncomfortable: calcium supplementation in women without adequate K2 may increase arterial calcification. Not dramatically. But measurably.
The mechanism is the K2 connection. Calcium needs to be actively directed. Without the K2-dependent proteins functioning properly, supplemental calcium circulates and can deposit where it shouldn't — arterial walls and soft tissue. With K2, those same proteins direct calcium into the bone matrix where it belongs.
What K2 actually does — the two proteins that matter
Vitamin K2 activates proteins through a process called carboxylation — adding a molecular arm that lets the protein bind calcium. Two proteins matter most for women.
Osteocalcin is produced by osteoblasts (the cells that build bone). In its uncarboxylated state, it can't grab calcium. K2 activates it so calcium can actually bind to the bone matrix — this is the mechanism behind K2's bone density benefits.
Matrix Gla Protein (MGP) is produced in arterial wall tissue. In its K2-activated state, it inhibits calcium from crystallizing in the arterial wall. In its inactive state — which occurs with K2 deficiency — arterial calcification accelerates. MGP is now considered one of the most potent inhibitors of vascular calcification known, and it's entirely K2-dependent.
The Rotterdam Study (Geleijnse et al., 2004) remains the landmark data set. In 4,807 Dutch adults followed for 10 years, those in the highest tertile of dietary K2 intake had 50% lower cardiovascular mortality, 57% lower severe aortic calcification, and 26% lower all-cause mortality compared to the lowest tertile. Crucially, dietary K1 (found in leafy greens) showed no such association — pointing specifically to K2's unique role in vascular protection, not vitamin K generally.
K1 vs. K2 — the distinction that most advice misses
Vitamin K1 (phylloquinone) is found abundantly in leafy green vegetables. It's involved in blood clotting and is generally adequate from diet. K2 (menaquinone) is found in fermented foods — natto, certain aged cheeses, some organ meats. Western diets are frequently K2-deficient because these foods aren't dietary staples.
The forms within K2 also differ. MK-4 is found in animal products and has a short half-life, meaning frequent dosing is needed. MK-7, derived from natto fermentation, has a half-life of approximately 72 hours and achieves stable blood levels with once-daily supplementation. The research on bone density and vascular health is predominantly with MK-7.
Look for MK-7 specifically (not just "vitamin K2"). Doses in the research range from 90–200 mcg daily. K2 is fat-soluble, so take it with a meal containing fat. D3 and K2 are often combined in supplements — this makes sense biologically, since D3 increases calcium absorption and K2 governs where that calcium goes. If you're on warfarin or any anticoagulant, confirm K2 supplementation with your prescribing doctor before starting.
Who should prioritize this conversation
Women taking calcium supplements, women with osteoporosis or low bone density, and women post-menopause (when bone loss accelerates) have the strongest case for discussing K2 with their doctor. If you've had coronary artery calcium scoring done and have elevated scores, K2 is relevant to ask about. If you are on warfarin, this is a non-negotiable conversation before supplementing.
References
- Geleijnse JM, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. Journal of Nutrition. 2004;134(11):3100–3105. doi:10.1093/jn/134.11.3100
- Knapen MH, et al. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporosis International. 2013;24(9):2499–2507. doi:10.1007/s00198-013-2325-6
- Booth SL, et al. Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. American Journal of Clinical Nutrition. 2000;71(5):1201–1208. doi:10.1093/ajcn/71.5.1201
- Schurgers LJ, Vermeer C. Determination of phylloquinone and menaquinones in food. Haemostasis. 2000;30(6):298–307. doi:10.1159/000054147